Srikumar Sahasranaman

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Lymph Node Metastasis

Top Venues

Clinical and translational science

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors. Clinical and translational science 17 (3) (2024)
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors. Clinical and translational science 17 (3) (2024)
Song Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, Iurie Bulat, Marina Maglakelidze, Viera Skarbova, Claudia Andreu-Vieyra, Srikumar Sahasranaman
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study. Cancer chemotherapy and pharmacology 88 (1) (2021)
Song Mu, Zhiyu Tang, William Novotny, Manal Tawashi, Ta-Kai Li, Ying Ou, Srikumar Sahasranaman
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer chemotherapy and pharmacology 85 (2) (2019)